Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Monopar Therapeutics

MNPR

113.9400.19% ( +0.220 )

Closed: Aug 27, 16:00:00 (EDT)

OverviewOverview OptionsOptions NewsNews PostsPosts FinancialsFinancials ForecastForecast ValuationValuation ShareholdersShareholders ProfileProfile

LongbridgeAI

Monopar Therapeutics director Raymond Anderson sells USD 349,125 of common shares
PUBT·7 hours ago
MNPR+0.19%
Weekly Recap | Monopar Therapeutics -4.71%, most brokers rate it buy
Weekly Review·Aug 22 at 12:13 AM
MNPR+0.19%
Monopar names Jeffrey D. Kent executive vice president, head of medical affairs
PUBT·Aug 19 at 07:03 AM
MNPR+0.19%
Monopar cut to neutral at Cantor on valuation
MSN·Aug 13 at 12:32 PM
MNPR+0.19%
This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
benzinga_article·Aug 13 at 11:09 AM
TROX+0.37%MNPR+0.19%
Boris Peaker Maintains Buy Rating on Monopar, Reaffirming Unchanged $130 Price Target on ALXN1840’s Strong Clinical and Regulatory Profile
Tip Ranks·Aug 12 at 04:15 PM
MNPR+0.19%
Monopar Therapeutics (NASDAQ:MNPR) Issues Quarterly Earnings Results, Misses Expectations By $0.13 EPS
Market Beat·Aug 12 at 11:26 AM
MNPR+0.19%
Monopar Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0
Earnings Watch·Aug 12 at 08:32 AM
MNPR+0.19%
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates | MNPR Stock News
StockTitan·Aug 12 at 12:30 AM
MNPR+0.19%
Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Wall Street Zen
Market Beat·Aug 8 at 01:12 AM
MNPR+0.19%
Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX
rttnews·Aug 7 at 05:33 AM
MNPR+0.19%ANRO-0.63%
MNPR Q2'26 Earnings: EPS estimate is (0.66) USD
TradingView·Aug 5 at 06:01 AM
MNPR+0.19%
Monopar Therapeutics (NASDAQ:MNPR) Reaches New 52-Week High - What's Next?
Market Beat·Jul 31 at 12:00 PM
- Monopar Therapeutics Inc. reached a new 52-week high of $116.69 per share alongside positive institutional activity and mixed analyst ratings. - The company maintains a market cap of $760.99 million with a consensus buy rating and a target price of $112.08. - Monopar operates as a clinical-stage biotechnology firm developing targeted radiotherapeutics and antibody-drug conjugates for cancer treatment.
MNPR+0.19%BAC-1.70%